For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.
Our values represent the very core of our character. They guide every decision and action we take.
Patients first: We are all accountable for delivering high-quality products and services. We aspire to improve the health and wellness of people and animals worldwide and to expand access to our medicines and vaccines. All of our actions must be measured against our responsibility to those who use or need our products.
Respect for people: Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity, safety, and teamwork of our employees. We work to create an environment of mutual respect, inclusion, and accountability. We reward commitment and performance and are responsive to the needs of our employees and their families.
Ethics and integrity: We are committed to the highest standards of ethics and integrity. We are responsible to all of our stakeholders: employees, patients, customers, distributors and suppliers, shareholders, and the communities we serve worldwide. We do not take professional or ethical shortcuts.
Innovation and scientific excellence: We are dedicated to the highest standard of innovation and scientific excellence. Our research is guided by a commitment to improving health and quality of life. We strive to identify and meet the most critical needs of patients and customers through continuous innovation across all areas of our business.
A Focus on Scientific Innovation to Deliver Medicines and Vaccines
We’re proud to deliver breakthrough innovations in oncology that are helping to extend the lives of patients with certain types of cancer. We’re continuing to accelerate what we can achieve for the patients we serve, because everyone needs more ways to treat their cancer and, hopefully, more time
Our team of researchers and scientists is pushing the boundaries of cancer research to discover more effective anticancer therapies.
· Cell-based therapies and T/NK cell engagers: Utilizing allogeneic T and NK cells and T/NK cell engagers that aim to attack tumors.
· Immune agonists: Molecules designed to stimulate immune system functions, such as enhancing the activity of anti-tumor immune cells.
· Inhibition of negative immune regulators: Designed to block the action of molecules that suppress the immune system to potentially enable a more robust anti-tumor response.
· Personalized cancer vaccines: Therapeutic vaccines based on patients’ specific cancer that could potentially prime the immune system to recognize certain characteristics and attack the cancer cells.
· Tumor microenvironment modulators: Seek to regulate the environment around tumors to influence how tumors grow and interact with the immune system.
Our work in vaccines focuses on making certain diseases a thing of the past.
· Experience in vaccines: We’ve been discovering, developing, and delivering vaccines to help prevent disease around the world for over 100 years. It is no secret that inventing and developing vaccines is complex, time-intensive, and carries no guarantees. To keep pace with the ever-evolving disease landscape, we continue to research candidates to address significant unmet needs.
· Collaboration and progress in vaccines: It takes active collaboration by our teams who partner with governments, academic researchers, and non-government organizations around the world. Our work in researching and producing vaccines is guided by science and fueled by human needs.
· Programs in vaccines: Inspired by the rich legacy and innovative spirit of the long-time scientist, Dr. Maurice Hilleman, we are proud to be engaging with the global health community through the MSD-Wellcome Trust Hilleman Laboratories. The mission of the Laboratories is to pursue innovation in vaccine science and technology that helps make access to vaccines more affordable and equitable in lower-income markets.
Our decades of research in infectious diseases have led to profound scientific advances. We’ve been combating global health threats caused by infectious diseases for more than a century. From developing one of the first antibiotics to pioneering research in HIV science, our focus has always been on the prevention and treatment of diseases that threaten people and communities around the world. But our work is far from done.
Every year, millions of people die from infectious diseases. The world is counting on us to bring forward new approaches to help ease human suffering.
· HIV: We remember when HIV was one of society’s most daunting challenges, when millions of people lost their lives to the devastating AIDS epidemic. Our scientists embarked on an urgent mission to unravel and understand the virus, which led to groundbreaking research in HIV.
· We are still driven to do more. We are pushing the boundaries of HIV science because unmet medical need still endures. Eradication of the virus is our ultimate goal.
· Antibiotics: While other companies pull away from antibiotic research and development, we stand out from the pack. We continue our efforts because we know the world needs it.
· Ebola: Since the emergence of the Ebola virus in 1976, periodic outbreaks have been a global health challenge. We are proud to be part of the global public-private partnership that has united the government, industry, community groups, scientists, healthcare workers, and ordinary people, to come together to help fight this deadly disease.
We have a long history of making an impact on cardio-metabolic disorders, such as type 2 diabetes and cardiovascular disease.
More than 60 years ago, we introduced our first cardiovascular therapy – and our scientific efforts to deeply understand cardio-metabolic disorders have continued
Cardio-metabolic disorders include cardiovascular diseases and metabolic diseases, such as type 2 diabetes. These represent some of the most serious health challenges of the 21st century.
Advancements in cardio-metabolic research can make an impactful difference for patients, and there is still much more work to be done. We strive for scientific excellence and innovation in all stages of research, from discovery through approval and afterward.
Robert M. Davis, Chairman, and chief executive officer
Rob Davis is chairman of the board and chief executive officer of Merck.
Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing, and Merck Research Laboratories. Prior to that, he was executive vice president, of Global Services, and the company’s chief financial officer.
Rob joined the company as a chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy, and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021, CEO and a member of the board of directors on July 1, 2021, and chairman of the board on December 1, 2022.
Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management, and his bachelor’s degree in finance from Miami University.
“Everything we do, in and out of the laboratory, is based on our deep appreciation for life. That’s the reason we come together across the business with one purpose — to use the power of leading-edge science to save and improve lives around the world.”